[{"id":"c02436a4-c327-4010-b280-df7280202ef3","acronym":"","url":"https://clinicaltrials.gov/study/NCT05688605","created_at":"2023-01-18T14:59:52.605Z","updated_at":"2024-07-02T16:35:57.487Z","phase":"Phase 1/2","brief_title":"A Study of MRG003 in the Treatment of Patients With EGFR-positive Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT05688605","lead_sponsor":"Shanghai Miracogen Inc.","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR positive","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Puyouheng (pucotenlimab) • Meiyouheng (becotatug vedotin)"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 06/30/2022","start_date":" 06/30/2022","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2023-01-18"},{"id":"1bac34f5-57ad-4236-9cb3-6af869cb8fb2","acronym":"","url":"https://clinicaltrials.gov/study/NCT05188209","created_at":"2022-01-12T15:53:51.462Z","updated_at":"2024-07-02T16:36:18.553Z","phase":"Phase 2","brief_title":"A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Advanced Gastric Cancer.","source_id_and_acronym":"NCT05188209","lead_sponsor":"Shanghai Miracogen Inc.","biomarkers":" EGFR • HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["EGFR • HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Meiyouheng (becotatug vedotin)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 05/24/2021","start_date":" 05/24/2021","primary_txt":" Primary completion: 03/21/2023","primary_completion_date":" 03/21/2023","study_txt":" Completion: 08/01/2023","study_completion_date":" 08/01/2023","last_update_posted":"2022-01-12"},{"id":"b01bfdf1-e7ef-45d9-99fd-e4d3a84b363f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04838964","created_at":"2021-04-09T16:56:10.530Z","updated_at":"2024-07-02T16:36:19.035Z","phase":"Phase 2","brief_title":"A Study of MRG003 in the Treatment of EGFR-positive Unresectable, Locally Advanced or Metastatic Biliary Tract Cancer","source_id_and_acronym":"NCT04838964","lead_sponsor":"Shanghai Miracogen Inc.","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR positive","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Meiyouheng (becotatug vedotin)"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 04/28/2021","start_date":" 04/28/2021","primary_txt":" Primary completion: 10/01/2024","primary_completion_date":" 10/01/2024","study_txt":" Completion: 11/01/2024","study_completion_date":" 11/01/2024","last_update_posted":"2021-12-29"},{"id":"e2d84696-64b6-495a-a910-c00f0219b393","acronym":"","url":"https://clinicaltrials.gov/study/NCT04868344","created_at":"2021-04-30T11:55:19.361Z","updated_at":"2024-07-02T16:36:30.948Z","phase":"Phase 1","brief_title":"A Study of MRG003 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT04868344","lead_sponsor":"Shanghai Miracogen Inc.","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR positive","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Meiyouheng (becotatug vedotin)"],"overall_status":"Completed","enrollment":" Enrollment 61","initiation":"Initiation: 05/09/2018","start_date":" 05/09/2018","primary_txt":" Primary completion: 03/29/2021","primary_completion_date":" 03/29/2021","study_txt":" Completion: 03/29/2021","study_completion_date":" 03/29/2021","last_update_posted":"2021-04-30"},{"id":"e152b491-718a-41e4-b7c8-11bb4e0088bb","acronym":"","url":"https://clinicaltrials.gov/study/NCT04838548","created_at":"2021-04-09T17:54:50.218Z","updated_at":"2024-07-02T16:36:32.149Z","phase":"Phase 2","brief_title":"A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With EGFR-Positive Advanced Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT04838548","lead_sponsor":"Shanghai Miracogen Inc.","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR expression • EGFR positive","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR expression • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Meiyouheng (becotatug vedotin)"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 09/04/2020","start_date":" 09/04/2020","primary_txt":" Primary completion: 12/01/2022","primary_completion_date":" 12/01/2022","study_txt":" Completion: 02/01/2023","study_completion_date":" 02/01/2023","last_update_posted":"2021-04-09"}]